Supports collaborative teams conducting integrated basic, translational, and clinical research on blood cancers. Grants fund multiple scientific projects and cores, emphasizing innovative approaches to treatment, diagnosis, or prevention. The 2026–2027 cycle targets Myelodysplastic Syndromes and other specified blood cancers, with flexibility for highly innovative proposals in related areas.
Eligible applicants are investigators worldwide with a PhD, MD, DVM, or equivalent degree affiliated with nonprofit academic institutions at the time of funding and throughout the award period.
